MustangBio
    • About
      • About Mustang Bio
      • Leadership
      • Board of Directors
      • In the News
      • Contact
    • Our Approach
      • Our Approach
      • About CAR T Cell Therapy
      • Publications
    • Pipeline
      • Pipeline
      • Clinical Trials
    • Partnering
      • Partnering
      • Active Collaborations
    • Careers
    • Investor Relations
      • News & Events
      • Company Info
      • Financial Info
      • Stock Data
      • SEC Filings
      • Governance

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    June 15, 2023

    Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

    June 12, 2023

    Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

    May 18, 2023

    Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

    May 12, 2023

    Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

    May 11, 2023

    Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

    April 3, 2023

    Mustang Bio Announces Reverse Stock Split

    March 29, 2023

    Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

    March 28, 2023

    Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium

    January 17, 2023

    Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

    December 19, 2022

    Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

    • arrow_back
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • …
    • 19
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    95 Sawyer Road, Suite 110 • Waltham, MA 02453

    781-652-4500 info@mustangbio.com

    Twitter Linkedin

    © Copyright 2025 Mustang Bio